Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Unwanted effects The fluoroquinolones absolutely are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they also are really modified quinolones, a category of an
The fluoroquinolones absolutely are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, sourced out of 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the one orally administered agents available for the treatment of serious infections attributable to gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have got a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important role in managing community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in children
Newer quinolones produce additional toxicities into the heart have been not found with the older agents
Fluoroquinolones advantages:
Ease in administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
Being a group, the fluoroquinolones have excellent in vitro activity against a large variety of both gram-positive and gram-negative bacteria. The present fluoroquinolones have enhanced activity against gram-positive bacteria with just the a decreased reduction in activity against gram-negative bacteria. Their expanded gram-positive activity is very important since it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were utilized primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing compared to the newer quinolones, plus they are also more susceptible to your development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, along with some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will probably be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin would be the hottest second-generation quinolones due to availability in oral and intravenous formulations as well as their broad pair of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated with a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for example Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they're less active than ciprofloxacin against Pseudomonas species.
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are of help in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that happen to be their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative workings of the third-generation drugs. Additionally they retain activity against Pseudomonas species similar to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
On account of worry about hepatotoxicity, trovafloxacin therapy really should be ready for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), along with the drug is critical for not than 14 days.
Unwanted effects
The fluoroquinolones as a class are generally well tolerated. Most uncomfortable side effects are mild in severity, self-limited, and rarely induce treatment discontinuation. However, they often have serious adverse effects.
Fluoroquinolones are approved for use only in people older than 18. They often affect the growth of bones, teeth, and cartilage inside a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating when these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will not be recommended unless the benefits justify the potential risks into the fetus. These agents are also excreted in breast milk and may even be bypassed during breast-feeding whether possible.
Gastrointestinal effects. A typical adverse events familiar with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur approx 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness are actually reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients with a tradition of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms for example dizziness occurred in about 50% of the patients.
Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight ought to be avoided during treatment and a few days (5 days with sparfloxacin) as the use of the drug. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the introduction of musculoskeletal effects, evident in animal studies, has led to your contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have already been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids.
Hepatoxicity. Trovafloxacin use has long been linked to rare liver damage, which prompted the withdrawal of many oral preparations coming from the U.S. market. However, the IV preparation is available for remedy for infections so serious that the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to supply additional toxicities to the heart that were not found together with the older compounds. Evidence means that sparfloxacin and grepafloxacin can have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results have already been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and can be mild to moderate in severity, and often resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have got a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important role in managing community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of a typical fluoroquinolones vary from 3 -20 hours, providing a couple of times daily dosing.
Author Resource:-
The fluoroquinolones really are a group of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of your group is nalidixic acid, taken from 1962 by Lescher and colleagues. The earliest fluoroquinolones were often since they were the only real orally administered agents intended for handling serious infections attributable to gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important part in treating community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in youngsters
Newer quinolones produce additional toxicities to your heart which were not found in the older constituents
Fluoroquinolones advantages:
No-fuss administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
To be a group, the fluoroquinolones have excellent in vitro activity against a wide variety of both gram-positive and gram-negative bacteria. The latest fluoroquinolones have enhanced activity against gram-positive bacteria with just the lowest decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is incredibly important because it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, comprehending the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing when compared to the newer quinolones, and are also more susceptible to your development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, along with some gram-positive and atypical pathogen coverage. In comparison to first-generation quinolones, these drugs have broader clinical applications throughout remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will probably be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and also their broad pair of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated inside third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, these are less active than ciprofloxacin against Pseudomonas species.
Because of the expanded antimicrobial spectrum, third-generation fluoroquinolones are of help in the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. Additionally they retain activity against Pseudomonas species corresponding to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
On account of bother about hepatotoxicity, trovafloxacin therapy should really be available to life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and also the drug is necessary for no more than 14 days.
Side effects
The fluoroquinolones to be a class some times well tolerated. Most adverse reactions are mild in severity, self-limited, and occasionally end in treatment discontinuation. However, they will be able to have serious adverse effects.
Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the development of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating which these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will never be recommended unless the positive aspects justify the potential risks to the fetus. These agents may also be excreted in breast milk and may even be ignored during breast-feeding if possible.
Gastrointestinal effects. A typical adverse effects informed about fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in a single to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have already been reported to all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients that has a tradition of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms for example dizziness happened in about 50% of the patients.
Phototoxicity. Experience with ultraviolet A rays from direct or indirect sunlight ought to be avoided during treatment and several other days (5 days with sparfloxacin) when by using the medication. The degree of phototoxic potential of fluoroquinolones can be as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Be worried about the building of musculoskeletal effects, evident in animal studies, has led to your contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within weeks time of discontinuation of therapy, spontaneous ruptures are actually reported so long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant consumption of corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be linked to rare liver damage, which prompted the withdrawal of many oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious the fact that benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to create additional toxicities into the heart which are not found in the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the outcome seem to have been mild.
Hypersensitivity. Hypersensitivity reactions occur very rarely during quinolone therapy and can be mild to moderate in severity, and usually resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important part in managing community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones diverge from 3 -20 hours, providing once or twice daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites